Journey Medical Corporation Launches Accutane for the Treatment of Severe Recalcitrant Nodular Acne

Written by  
Fortress Biotech’s Partner Company, Journey Medical Corporation, In-licenses and Launches Accutane® for the Treatment of Severe Recalcitrant Nodular Acne Fortress Biotech’s Partner Company, Journey Medical Corporation, In-licenses and Launches Accutane® for the Treatment of Severe Recalcitrant Nodular Acne

Accutane is Journey Medical’s sixth marketed dermatology product

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that Journey Medical Corporation (“Journey Medical”), a partner company of Fortress, in-licensed and launched oral isotretinoin under the brand name Accutane® (isotretinoin capsules USP) in the U.S. Accutane is an oral medication that is indicated for the treatment of severe recalcitrant nodular acne. It is only available by prescription at major U.S. retail and specialty pharmacy chains.

Claude Maraoui, President and Chief Executive Officer of Journey Medical, stated, “We are proud to add Accutane to our growing portfolio of dermatology products, which also includes Targadox® (doxycycline Hyclate tablets USP) and Ximino® (minocycline hydrochloride extended-release capsules). Licensing and launching Accutane allows us to leverage the strength of its brand name with our experienced acne sales team. We are poised for an exciting year as we launch this brand under the Journey Medical umbrella.”

Acne is one of the most commonly treated disease states in dermatology. Acne is most common among teenagers, though it affects people of all ages. Accutane belongs to a class of drugs that may affect all four major pathogenic processes in acne: increased sebum production, irregular follicular desquamation, propionibacterium acnes proliferation, and inflammation. Over 1.8 million prescriptions were written for all isotretinoin products in 2020, according to Symphony Health.

Lindsay A. Rosenwald, M.D., Chairman, President, and Chief Executive Officer of Fortress, added, “The in-licensing of Accutane and expansion of Journey Medical’s portfolio of branded dermatology products showcases Fortress’s unique business model designed to acquire and rapidly advance overlooked yet potentially transformative assets to patients. We are excited about the growth potential that this newly acquired product will bring to our revenue-generating partner company.”

For full prescribing information about Accutane, please visit www.rxaccutane.com.






Want to read more?

Subscribe to one of our monthly plans to continue reading this article.

Login to post comments

February 2024

Brands of the Month

  • Face Reality Skincare
  • Skin Script
  • Repechage

Trending Industry News

body { overflow-y: auto; } html, body { min-width: unset; }